| Name | Dapagliflozin ((2S)-1,2-propanediol, hydrate) |
| Description | Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2), in development for treating type 2 diabetes mellitus (T2DM). It inhibits SGLT2, responsible for at least 90% of glucose reabsorption in the kidney. |
| In vitro | Dapagliflozin (2S)-1,2-propanediol, hydrate is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin inhibits sodium/glucose cotransporter 2 (SGLT2), which results in excretion of glucose into the urine. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (99.41 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.98 mM), Sonication is recommended.
|
| Keywords | Sodium-dependent glucose cotransporters | SGLT2 | SGLT | Inhibitor | inhibit | Dapagliflozin propanediol Monohydrate | Dapagliflozin propanediol | Dapagliflozin (1,2-propanediol, hydrate) | Dapagliflozin ((2S)1,2propanediol, hydrate) | Dapagliflozin ((2S) 1,2 propanediol, hydrate) | BMS-512148 1,2-propanediol, Hydrate |
| Inhibitors Related | Ertugliflozin L-pyroglutamic acid | Dapagliflozin | Ipragliflozin | Sotagliflozin | Canagliflozin hemihydrate | Tofogliflozin (hydrate) | Phlorizin | Phloretin | Sergliflozin A | Empagliflozin | Canagliflozin | Ertugliflozin |
| Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
